Israeli M&A: Teva Sells Oncotest to Rhenium

Israeli M&A Teva Sells Oncotest to Rhenium

Generic drug producer Teva Pharmaceuticals (TEVA) will sell genetic testing services venture Oncotest to an Israeli company called Rhenium, reports sources. It is believed that the payment will be in the “tens of millions of dollars.”
Teva is one of the largest generic drug producers in the world. Over time, they have also diversified acquiring branded assets in the pursuit to become a fully integrated global biopharmaceutical drug company.
The Deal
Founded in 1968 by Dr. Lior Soussan-Gutman, the company markets laboratory tests in Israel from all over the world in an effort to map malignant tumors and adjust treatments for clinical trials specifically to the patient’s tumor. 100% owned by Teva, they are selling their entire ownership to Rhenium.
Who is Rhenium? 
Rhenium was founded and managed by Dror Israeli, a company that specializes in marketing equipment for laboratory tests to private laboratories, health funds, and hospitals. Founded in 1991, the company operates in Modi'in. Shamrock Israel Growth Fund, the Disney family’s investment fund in Israel, invested tens of millions in Rhenium for 30% of the company.
Background
Oncotest has been a pioneer in genetic testing ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee